Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 85

1.

3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT.

Iveson T, Boyd KA, Kerr RS, Robles-Zurita J, Saunders MP, Briggs AH, Cassidy J, Hollander NH, Tabernero J, Haydon A, Glimelius B, Harkin A, Allan K, McQueen J, Pearson S, Waterston A, Medley L, Wilson C, Ellis R, Essapen S, Dhadda AS, Harrison M, Falk S, Raouf S, Rees C, Olesen RK, Propper D, Bridgewater J, Azzabi A, Farrugia D, Webb A, Cunningham D, Hickish T, Weaver A, Gollins S, Wasan H, Paul J.

Health Technol Assess. 2019 Dec;23(64):1-88. doi: 10.3310/hta23640.

2.

How do clinicians rate patient's performance status using the ECOG performance scale? A mixed-methods exploration of variability in decision-making in oncology.

Datta SS, Ghosal N, Daruvala R, Chakraborty S, Shrimali RK, van Zanten C, Parry J, Agrawal S, Atreya S, Sinha S, Chatterjee S, Gollins S.

Ecancermedicalscience. 2019 Mar 28;13:913. doi: 10.3332/ecancer.2019.913. eCollection 2019.

3.

SCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer.

Robles-Zurita J, Boyd KA, Briggs AH, Iveson T, Kerr RS, Saunders MP, Cassidy J, Hollander NH, Tabernero J, Segelov E, Glimelius B, Harkin A, Allan K, McQueen J, Pearson S, Waterston A, Medley L, Wilson C, Ellis R, Essapen S, Dhadda AS, Hughes R, Falk S, Raouf S, Rees C, Olesen RK, Propper D, Bridgewater J, Azzabi A, Farrugia D, Webb A, Cunningham D, Hickish T, Weaver A, Gollins S, Wasan HS, Paul J.

Br J Cancer. 2018 Nov;119(11):1332-1338. doi: 10.1038/s41416-018-0319-z. Epub 2018 Nov 13.

4.

Factors affecting local regrowth after watch and wait for patients with a clinical complete response following chemoradiotherapy in rectal cancer (InterCoRe consortium): an individual participant data meta-analysis.

Chadi SA, Malcomson L, Ensor J, Riley RD, Vaccaro CA, Rossi GL, Daniels IR, Smart NJ, Osborne ME, Beets GL, Maas M, Bitterman DS, Du K, Gollins S, Sun Myint A, Smith FM, Saunders MP, Scott N, O'Dwyer ST, de Castro Araujo RO, Valadao M, Lopes A, Hsiao CW, Lai CL, Smith RK, Paulson EC, Appelt A, Jakobsen A, Wexner SD, Habr-Gama A, Sao Julião G, Perez R, Renehan AG.

Lancet Gastroenterol Hepatol. 2018 Dec;3(12):825-836. doi: 10.1016/S2468-1253(18)30301-7. Epub 2018 Oct 12.

5.

Systematic review of treatment intensification using novel agents for chemoradiotherapy in rectal cancer.

Clifford R, Govindarajah N, Parsons JL, Gollins S, West NP, Vimalachandran D.

Br J Surg. 2018 Nov;105(12):1553-1572. doi: 10.1002/bjs.10993.

6.

Results of a multicentre randomised controlled trial of cochlear-sparing intensity-modulated radiotherapy versus conventional radiotherapy in patients with parotid cancer (COSTAR; CRUK/08/004).

Nutting CM, Morden JP, Beasley M, Bhide S, Cook A, De Winton E, Emson M, Evans M, Fresco L, Gollins S, Gujral D, Harrington K, Joseph M, Lemon C, Luxon L, van den Blink Q, Mendes R, Miah A, Newbold K, Prestwich R, Robinson M, Sanghera P, Simpson J, Sivaramalingam M, Srihari NN, Sydenham M, Wells E, Witts S, Hall E; COSTAR Investigators.

Eur J Cancer. 2018 Nov;103:249-258. doi: 10.1016/j.ejca.2018.08.006. Epub 2018 Oct 1.

7.

A prospective phase II study of pre-operative chemotherapy then short-course radiotherapy for high risk rectal cancer: COPERNICUS.

Gollins S, West N, Sebag-Montefiore D, Susnerwala S, Falk S, Brown N, Saunders M, Quirke P, Ray R, Parsons P, Griffiths G, Maughan T, Adams R, Hurt C.

Br J Cancer. 2018 Sep;119(6):697-706. doi: 10.1038/s41416-018-0209-4. Epub 2018 Aug 17.

8.

Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study.

van der Valk MJM, Hilling DE, Bastiaannet E, Meershoek-Klein Kranenbarg E, Beets GL, Figueiredo NL, Habr-Gama A, Perez RO, Renehan AG, van de Velde CJH; IWWD Consortium.

Lancet. 2018 Jun 23;391(10139):2537-2545. doi: 10.1016/S0140-6736(18)31078-X.

PMID:
29976470
9.

In Reply to Habr-Gama et al.

Sun Myint A, Smith FM, Gollins S, Rao C, Pritchard DM.

Int J Radiat Oncol Biol Phys. 2018 Jul 1;101(3):743-744. doi: 10.1016/j.ijrobp.2018.03.033. No abstract available.

PMID:
29893284
10.

Evaluation of pre-analytical factors affecting plasma DNA analysis.

Markus H, Contente-Cuomo T, Farooq M, Liang WS, Borad MJ, Sivakumar S, Gollins S, Tran NL, Dhruv HD, Berens ME, Bryce A, Sekulic A, Ribas A, Trent JM, LoRusso PM, Murtaza M.

Sci Rep. 2018 May 9;8(1):7375. doi: 10.1038/s41598-018-25810-0.

11.

3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial.

Iveson TJ, Kerr RS, Saunders MP, Cassidy J, Hollander NH, Tabernero J, Haydon A, Glimelius B, Harkin A, Allan K, McQueen J, Scudder C, Boyd KA, Briggs A, Waterston A, Medley L, Wilson C, Ellis R, Essapen S, Dhadda AS, Harrison M, Falk S, Raouf S, Rees C, Olesen RK, Propper D, Bridgewater J, Azzabi A, Farrugia D, Webb A, Cunningham D, Hickish T, Weaver A, Gollins S, Wasan HS, Paul J.

Lancet Oncol. 2018 Apr;19(4):562-578. doi: 10.1016/S1470-2045(18)30093-7.

12.

A Prospective Phase I/II Study of Docetaxel, Cisplatin and Continuous Capecitabine in Advanced Oesophago-Gastric Cancer (NWCOG-3).

Gollins S, Massalha S, Mullard A, Williams RM, Lloyd A, Morris J, Garcia-Alonso A.

Clin Oncol (R Coll Radiol). 2018 Jul;30(7):409-417. doi: 10.1016/j.clon.2018.03.002. Epub 2018 Mar 21.

PMID:
29573846
13.

Prospective patient stratification into robust cancer-cell intrinsic subtypes from colorectal cancer biopsies.

Alderdice M, Richman SD, Gollins S, Stewart JP, Hurt C, Adams R, McCorry AM, Roddy AC, Vimalachandran D, Isella C, Medico E, Maughan T, McArt DG, Lawler M, Dunne PD.

J Pathol. 2018 May;245(1):19-28. doi: 10.1002/path.5051. Epub 2018 Mar 25.

14.

A Cost-Effectiveness Analysis of Contact X-ray Brachytherapy for the Treatment of Patients with Rectal Cancer Following a Partial Response to Chemoradiotherapy.

Rao C, Smith FM, Martin AP, Dhadda AS, Stewart A, Gollins S, Collins B, Athanasiou T, Sun Myint A.

Clin Oncol (R Coll Radiol). 2018 Mar;30(3):166-177. doi: 10.1016/j.clon.2017.11.015. Epub 2017 Dec 14.

PMID:
29248311
15.

Dose Escalation Using Contact X-ray Brachytherapy After External Beam Radiotherapy as Nonsurgical Treatment Option for Rectal Cancer: Outcomes From a Single-Center Experience.

Sun Myint A, Smith FM, Gollins S, Wong H, Rao C, Whitmarsh K, Sripadam R, Rooney P, Hershman M, Pritchard DM.

Int J Radiat Oncol Biol Phys. 2018 Mar 1;100(3):565-573. doi: 10.1016/j.ijrobp.2017.10.022. Epub 2017 Oct 20.

PMID:
29229327
16.

Dose escalation using contact X-ray brachytherapy (Papillon) for rectal cancer: does it improve the chance of organ preservation?

Sun Myint A, Smith FM, Gollins SW, Wong H, Rao C, Whitmarsh K, Sripadam R, Rooney P, Hershman MJ, Fekete Z, Perkins K, Pritchard DM.

Br J Radiol. 2017 Dec;90(1080):20170175. doi: 10.1259/bjr.20170175. Epub 2017 Nov 10.

17.

Preoperative chemoradiation with capecitabine, irinotecan and cetuximab in rectal cancer: significance of pre-treatment and post-resection RAS mutations.

Gollins S, West N, Sebag-Montefiore D, Myint AS, Saunders M, Susnerwala S, Quirke P, Essapen S, Samuel L, Sizer B, Worlding J, Southward K, Hemmings G, Tinkler-Hundal E, Taylor M, Bottomley D, Chambers P, Lawrie E, Lopes A, Beare S.

Br J Cancer. 2017 Oct 24;117(9):1286-1294. doi: 10.1038/bjc.2017.294. Epub 2017 Aug 31.

18.

Talking about human papillomavirus and cancer: development of consultation guides through lay and professional stakeholder coproduction using qualitative, quantitative and secondary data.

Hendry M, Pasterfield D, Gollins S, Adams R, Evans M, Fiander A, Robling M, Campbell C, Bekkers MJ, Hiscock J, Nafees S, Rose J, Stanley M, Williams O, Makin M, Wilkinson C.

BMJ Open. 2017 Jun 26;7(6):e015413. doi: 10.1136/bmjopen-2016-015413.

19.

Association of Coloproctology of Great Britain & Ireland (ACPGBI): Guidelines for the Management of Cancer of the Colon, Rectum and Anus (2017) - Anal Cancer.

Geh I, Gollins S, Renehan A, Scholefield J, Goh V, Prezzi D, Moran B, Bower M, Alfa-Wali M, Adams R.

Colorectal Dis. 2017 Jul;19 Suppl 1:82-97. doi: 10.1111/codi.13709. No abstract available.

PMID:
28632308
20.

Association of Coloproctology of Great Britain & Ireland (ACPGBI): Guidelines for the Management of Cancer of the Colon, Rectum and Anus (2017) - Multidisciplinary Management.

Gollins S, Moran B, Adams R, Cunningham C, Bach S, Myint AS, Renehan A, Karandikar S, Goh V, Prezzi D, Langman G, Ahmedzai S, Geh I.

Colorectal Dis. 2017 Jul;19 Suppl 1:37-66. doi: 10.1111/codi.13705. No abstract available.

PMID:
28632307

Supplemental Content

Loading ...
Support Center